Physician profile

Jonathan M Cox

Cardiovascular Disease · Philadelphia, PA

NPI 1013987544

$4,804.31

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $741.39 2019-2021
Pfizer INC. $568.15 2019-2021
Amarin Pharma, INC. $532.55 2019-2021
Janssen Pharmaceuticals, INC $523.27 2019-2021
Boston Scientific Corporation $417.66 2019-2022
Sanofi-Aventis U.S. LLC $403.73 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $255.02 2019-2022
Janssen Biotech, INC. $171.99 2019-2021
Astellas Pharma US INC $158.79 2019-2021
Regeneron Healthcare Solutions, INC. $145.63 2019-2021
Kowa Pharmaceuticals America, INC. $133.91 2019-2022
Esperion Therapeutics, INC. $125.46 2021
Gilead Sciences, INC. $112.37 2019
Astrazeneca Pharmaceuticals LP $107.30 2019-2021
E.R. Squibb & Sons, L.L.C. $91.07 2019-2021
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $76.85 2019-2021
Althera Pharmaceuticals LLC $65.85 2021
Merck Sharp & Dohme LLC $57.41 2021
Impulse Dynamics (USA) INC. $46.28 2022
Abbott Laboratories $34.70 2019-2021
Medtronic, INC. $22.35 2021
Kiniksa Pharmaceuticals, LTD. $12.58 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jonathan M Cox

$4,804.31

in general payments reported 2019-2025

Years
2019-2022
Top company
Amgen INC.

https://glasscript.com/doctor/182589/jonathan-m-cox

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.